FDA Waxman/Hatch “Moot Court” Will Examine Brand/Generic Legal Positions
Executive Summary
FDA's chief counsel will be hosting a "moot court" to receive a thorough briefing on the brand and generic industry arguments about the agency's interpretation of the Waxman/Hatch Act
You may also be interested in...
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan
FDA Waxman/Hatch Policy Change Afforded Full White House Honors
The White House Waxman/Hatch reform proposal reflects the policy development approach of FDA Chief Counsel Daniel Troy - and the Administration-insider status of incoming Commissioner Mark McClellan
FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?
FDA is requesting comment on the legal underpinnings for arguing that promotions of prescription drugs can be more tightly regulated than those for other products